Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.

F H Valone; P A Kaufman; P M Guyre; L D Lewis; V Memoli; Y Deo; R Graziano; J L Fisher; L Meyer; M Mrozek-Orlowski

doi:10.1200/JCO.1995.13.9.2281

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.

Identifier:nobleid.org/w1/20260515/089082AB

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/089082AB.svg?ark=w1%2F20260515%2F089082AB)](https://nobleid.org/work/w1/20260515/089082AB)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.

Identifier:nobleid.org/w1/20260515/089082AB

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/089082AB.svg?ark=w1%2F20260515%2F089082AB)](https://nobleid.org/work/w1/20260515/089082AB)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work